Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting

Deepa Rangachari¹, Paul A VanderLaan², Daniel B Costa³

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
³ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: dbcosta@bidmc.harvard.edu.

PMID: 29703544
DOI: 10.1016/j.jtho.2018.01.023

Free article

Comment

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting

Deepa Rangachari et al. J Thorac Oncol. 2018 May.

Free article

. 2018 May;13(5):e81-e83.

doi: 10.1016/j.jtho.2018.01.023.

Authors

Deepa Rangachari¹, Paul A VanderLaan², Daniel B Costa³

Affiliations

¹ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
³ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: dbcosta@bidmc.harvard.edu.

PMID: 29703544
DOI: 10.1016/j.jtho.2018.01.023

No abstract available

PubMed Disclaimer

Comment on

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Rangachari D, et al. J Thorac Oncol. 2017 May;12(5):878-883. doi: 10.1016/j.jtho.2016.12.026. Epub 2017 Jan 16. J Thorac Oncol. 2017. PMID: 28104537 Free PMC article.
Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
Miyawaki E, Murakami H, Takahashi T. Miyawaki E, et al. J Thorac Oncol. 2018 May;13(5):e79-e81. doi: 10.1016/j.jtho.2018.01.011. J Thorac Oncol. 2018. PMID: 29703543 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting

Affiliations

Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous